1.	Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: LAP-R2007, NCT00504764
2.	LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: PETHEMA-LAM07, NCT01041040
3.	Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Phase: Phase III, Phase II Type: Treatment Status: Active Age: 61 and over Sponsor: Other Protocol IDs: EORTC-06031, NCT00091234
4.	Phase II/III Randomized Study of Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: UHW-AML16, EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480
5.	Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML) Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: MYFLAI07, NCT00909168
6.	Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk Phase: Phase III Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: BRD 06/10-I, NCT00860639
7.	Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: AMLSG 09-09, NCT00893399
8.	Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: EK 92062003, NCT00460447
9.	Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: 07-154, NCT00660036
10.	A Trial of the Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 90 Sponsor: Other Protocol IDs: 090516, NCT00766116
11.	Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 50 and over Sponsor: NCI Protocol IDs: NCI-2012-01147, R21CA139455, 2288.00, FHCRC-2288.00, 8297, IR-6921, NCT00895934
12.	Bendamustine Hydrochloride and Idarubicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase: Phase II, Phase I Type: Treatment Status: Active Age: 60 and over Sponsor: NCI, Other Protocol IDs: 2413.00, NCI-2010-01253, K12CA076930, NCT01141725
13.	Phase II Study of Induction and Consolidation Therapy Comprising Tretinoin, Arsenic Trioxide, and Gemtuzumab Ozogamicin Followed by Maintenance Therapy Comprising Tretinoin, Mercaptopurine, and Methotrexate in Patients With Previously Untreated, High-Risk Acute Promyelocytic Leukemia Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S0535, S0535, NCT00551460
14.	Fludarabine, Cytarabine, Filgrastim and Idarubicin in Core Binding Factor (CBF) Leukemias Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2007-0147, NCT00801489
15.	Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 50 and over Sponsor: Other Protocol IDs: 2009-08-029, NCT01039363
16.	Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Phase: Phase II Type: Treatment Status: Active Age: Any age Sponsor: NCI, Other Protocol IDs: 2240.00, NCI-2010-00281, P01CA078902, NCT01083706
17.	Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin Phase: Phase II Type: Treatment Status: Active Age: 10 and over Sponsor: Other Protocol IDs: 2010-0981, NCT01409161